TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: in CML stem cells is due to TGF-β1 in the microenvironment, and that the treatment of human CML stem cells with a TGF-β1 inhibitor inhibited their clonogenic activity in vitro [15].